Drug pedigree rule on hold
A federal court ruling blocks FDA from enforcing the pharmaceutical pedigree requirements set forth in the Prescription Drug Marketing Act. The bench ruling was issued Dec. 4 by Judge Joanna Seybert of the U.S. District Court for the Eastern District of New York. Secondary distributors RxUSA Wholesale, Alden Surgical, Atlantic Biologics, Bell Medical Services, Truxton, Hygen Pharmaceuticals and Stat Pharmaceuticals filed for the preliminary injunction Sept. 20, seeking to prevent FDA from implementing the final pedigree rule. Magistrate Judge Kathleen Tomlinson recommended Nov. 30 that the district court grant the preliminary injunction, saying that plaintiffs have demonstrated the provision of the PDMA exempting authorized distributors from pedigree requirements may be ruled unconstitutional. FDA announced this summer that it would allow to expire a more than 10-year long stay that has delayed implementation of the PDMA pedigree requirements (1"The Pink Sheet" July, 10, 2006, p. 15)...
You may also be interested in...
With testimony that fewer than one in seven pharmaceutical manufacturers could be ready for California's planned implementation of electronic pedigree rules on Jan. 1, 2009, the State Board of Pharmacy decided to delay implementation for another two years
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.